SM
NKTR icon

Sabby Management’s Nektar Therapeutics NKTR Stock Holding History

Sabby Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-43
Closed -$2.14M – 105
2018
Q4 		$2.14M Buy
43
+4
+10% +$2.42K 0.47% 26
2018
Q3 		$3.61M Sell
39
-5
-11% -$4.27K 0.46% 32
2018
Q2 		$3.19M Sell
44
-4
-8% -$4.61K 0.49% 32
2018
Q1 		$7.7M Buy
48
+11
+30% +$14.2K 0.92% 18
2017
Q4 		$3.33M Buy
+37
New +$21.9K 0.3% 42
2017
Q1 		– Sell
-7
Closed -$135K – 290
2016
Q4 		$135K Buy
+7
New +$1.42K 0.01% 260
2015
Q1 		– Sell
-159
Closed -$3.69K – 315
2014
Q4 		$3.69K Buy
+159
New +$34K 0.12% 84
2013
Q4 		– Sell
-44
Closed -$686K – 239
2013
Q3 		$686K Buy
+44
New +$8.13K 0.04% 147

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sabby Management's NKTR Position: Q1 2019 in Review

Sabby Management sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 5,261 shares — an estimated $2.59M sold.

Sabby Management first reported a position in NKTR in Q4 2013 and held it in 8 quarters. The position peaked at $18M in Q3 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Sabby Management reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Sabby Management sold 5,261 Nektar Therapeutics shares in Q1 2019, an estimated $2.59M.
  • Sabby Management first reported a position in Nektar Therapeutics in Q4 2013 and held it in 8 quarters.
  • Sabby Management's Nektar Therapeutics position peaked at $18M in Q3 2018.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.